Key result
Ultra-long second-generation DES linked to ~67% higher TLR rates.
Why the study?
Long stenting is a known predictor of stent thrombosis or target lesion revascularization in first-generation DES, but safety and prognosis of ultra-long second-generation DES implantation in real-world practice were unclear.
Does ultra-long second-generation DES implantation increase target lesion revascularization compared to shorter DES in patients undergoing percutaneous coronary intervention?
Cohort (n=1,669)
Does ultra-long second-generation DES implantation increase target lesion revascularization compared to shorter DES in patients undergoing percutaneous coronary intervention?
Relative Risk: 1.67 (95% CI 1.07–2.55)
p-value: p=0.02
Ultra-long second-generation DES implantation (>50 mm) is associated with an increased risk of target lesion revascularization but does not increase the risk of stent thrombosis compared to shorter stents.
Ultra-long second-generation DES associated with higher TLR; hypothesis-generating and should not yet change practice.
OBJECTIVES: This study investigated the safety and prognosis of ultra-long second DES (UL-2nd DES) implantation in real-world practice. BACKGROUND: Long stenting is a widely known predictor of stent thrombosis (ST) or target lesion revascularization (TLR) in first-generation drug-eluting stents (DES). METHODS: Participants were 1,669 patients (2,763 lesions) who had undergone successful second DES implantation; they were assigned to one of three groups: ultra-long 2nd DES (UL-DES; >50 mm, 166 patients, 259 lesions), long second DES (L-DES; 20-50 mm, 758 patients, 1,212 lesions), or short second DES (S-DES; <20 mm, 745 patients, 1,292 lesions). The primary endpoint was TLR, and secondary endpoints were ST, cardiac death, and major adverse cardiac events (MACE; composite of TLR, ST and cardiac death). A Cox proportional hazards model was used to identify independent predictors of TLR. RESULTS: Patient characteristics including dual antiplatelet therapy duration were similar across groups. Follow-up data were obtained from hospital charts, by contacting patients. Target lesion characteristics in the UL-DES group showed higher right coronary artery and chronic total occlusion lesion rates. TLR rates (23.1 ± 13.2 months) were significantly higher in the UL-DES group relative to other groups during follow up (P < 0.001). TLR rate was similar between S-DES and L-DES (P = 0.30). The incidence of ST was similar across groups (P = 0.40). MACE was significantly higher in the UL-DES group relative to other groups due to higher TLR rates (P = 0.01). In a Cox proportional hazard model, hemodialysis (RR: 2.53, 95% CI: 1.69-3.67, P < 0.001) and total stent length of >50 mm (RR: 1.67, 95% CI: 1.07-2.55, P = 0.02) were independent predictors of TLR. CONCLUSIONS: Ultra-long DES implantation was associated with higher TLR rates but did not increase ST, while long DES implantation up to 50 mm was safe and acceptable.
No takes yet. Share an insight, caveat, or question.
Honda et al. (2015) conducted a cohort in Coronary artery disease requiring stenting (n=1,669). Ultra-long second-generation drug-eluting stent (>50 mm) vs. Long (20-50 mm) or short (<20 mm) second-generation drug-eluting stents was evaluated on Target lesion revascularization (TLR) (RR 1.67, 95% CI 1.07-2.55, p=0.02). Ultra-long second-generation drug-eluting stent implantation (>50 mm) was an independent predictor of higher target lesion revascularization rates (RR 1.67; 95% CI 1.07-2.55; P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: